Mounjaro®
Starting from £179.99/mo
Start journey Learn moreCrisps on Mounjaro: technically yes, they are not forbidden, but many people find their appetite for salty snacks shifts considerably once tirzepatide starts working. Mounjaro is a once-weekly prescription injection that slows how quickly your stomach empties and dials down appetite signals — so the handful of crisps that barely registered before may now feel like a full meal. The real question is not whether you can eat crisps, but how they fit into the decisions you are making about food on treatment. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber decides whether it is clinically suitable for you, and personalised dietary guidance is part of that clinical picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) that are both involved in signalling fullness and regulating how quickly food moves through the stomach. When gastric emptying slows, food sits in the stomach longer. That changes how your body processes a snack like crisps, which are typically high in fat. Fat already slows gastric emptying on its own; add tirzepatide to that and a modest portion can sit heavily, triggering bloating, reflux or nausea that would not have happened before.
Many people also report that Mounjaro seems to quiet food noise, the background hum of cravings that drives reaching for snacks between meals. For some, the pull towards salty, crunchy foods reduces noticeably within the first few weeks. For others it stays, but portion tolerance drops: a small bag might be all that feels manageable before discomfort kicks in. Neither response is wrong; they reflect normal individual variation in how the medicine works.
If you want to understand more about how eating in general changes on Mounjaro, the picture is broader than crisps alone, but crisps are a useful test case because they combine fat, salt, low protein and low fibre in one go.
There is no clinical rule banning crisps on tirzepatide. What clinical guidance consistently points to, though, is making the most of a reduced appetite by choosing foods with protein and fibre first, because those are the nutrients most people on a calorie deficit risk under-consuming. The NHS tirzepatide information page notes that treatment works alongside a reduced-calorie diet and increased activity, the medicine creates the window; what you eat shapes how well you use it.
In practice this means: if you have already had a meal with good protein and you want a small portion of crisps, the evidence does not suggest that will derail treatment. The concern arises when crisps or similar snacks displace more nutritious food from an already smaller eating window, or when they aggravate GI symptoms. Nausea is the most commonly reported side effect of Mounjaro, and fatty, heavily salted foods are reliably among the things that make it worse, particularly after a dose increase.
For a fuller picture of the foods that tend to sit well and those that don't, our guide to eating on Mounjaro covers the practical framework most people find helpful. There is also a companion piece on chips and similar fried foods for anyone navigating similar questions about hot snacks.
One thing worth knowing: appetite suppression on Mounjaro is not uniform across the week. Many people find their appetite is most reduced in the day or two after their injection and gradually returns as the week goes on. That means a craving for crisps (or any snack) is more likely to resurface towards the end of the week, and that is normal, not a sign the medicine has stopped working.
The bigger pattern to watch is whether snacking is filling a gap that a more balanced meal could fill instead. People who find they struggle to eat much at all on Mounjaro sometimes end up grazing on whatever is available, including crisps, simply because a proper meal feels impossible. If that is happening to you, it is worth raising with your prescriber, it affects how well your body gets what it needs over the months of treatment.
NICE's appraisal of tirzepatide notes that treatment is reviewed at six months; if weight loss is below a certain threshold, the clinical picture is reassessed. What you eat during that window matters, and that conversation belongs with your clinical team rather than a general food rule. For a broader look at how much flexibility you actually have on treatment, or to read through specific food guidance from a clinical perspective, those pages go into more depth.
If you have questions about diet and Mounjaro that belong in a proper clinical conversation, you can speak to our prescribers through a free consultation, same-day review by a real clinician, not a checklist.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.